The Department of Health of South Africa released Interim clinical guidance for the implementation of injectable-free regimens for rifampicin-resistant tuberculosis in adults, adolescents and children.
The document provides interim clinical guidance on implementation of the modified short and long treatment regimens for people with rifampicin-resistant TB (RR-TB) in South Africa following the release of the WHO Rapid Communication: Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB).
National guidelines will be revised in 2019 following publication of the updated WHO policy guidelines on MDR-TB treatment (expected later in 2018).